1
|
Celis J, Ringborg U. From the creation of the European research area in 2000 to a Mission on cancer in Europe in 2021-lessons learned and implications. Mol Oncol 2024; 18:785-792. [PMID: 38468400 PMCID: PMC10994226 DOI: 10.1002/1878-0261.13632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2024] [Revised: 03/09/2024] [Accepted: 02/29/2024] [Indexed: 03/13/2024] Open
Abstract
In the year 2000, cancer research in Europe had the potential to make a difference as it had several unique strengths, such as a strong foundation in biomedical science, good patient registries, infrastructures that spanned from biological repositories to bioinformatic hubs as well as thriving Comprehensive Cancer Centers (CCCs) and basic/preclinical cancer research institutions of high international standing. Research, however, was fragmented and lacked coordination. As a result, Europe could not harness its potential for translating basic research discoveries into a clinical setting for the patients' benefit. What was needed was a paradigm shift in cancer research that addressed the translational research continuum. Along these lines, in 2000, European Union (EU) Commissioner Philippe Busquin established the European Research Area (ERA) and in 2002 the European Cancer Research Area (ECRA), and their political approval was a powerful catalyst for the increased involvement of scientists in science policy in the EU. In this report, we briefly describe the actions embraced by the cancer community and cancer organizations in response to Busquin's proposals that led to the creation of the EU Mission on Cancer (MoC) in Horizon 2020 in 2021.
Collapse
Affiliation(s)
- Julio Celis
- Danish Cancer SocietyCopenhagenDenmark
- European Academy of Cancer SciencesStockholmSweden
| | - Ulrik Ringborg
- European Academy of Cancer SciencesStockholmSweden
- Karolinska InstitutetStockholmSweden
- Cancer Center KarolinskaKarolinska University Hospital SolnaStockholmSweden
| |
Collapse
|
2
|
Ringborg U, von Braun J, Celis J, Baumann M, Berns A, Eggermont A, Heard E, Heitor M, Chandy M, Chen C, Costa A, De Lorenzo F, De Robertis EM, Dubee FC, Ernberg I, Gabriel M, Helland Å, Henrique R, Jönsson B, Kallioniemi O, Korbel J, Krause M, Lowy DR, Michielin O, Nagy P, Oberst S, Paglia V, Parker MI, Ryan K, Sawyers CL, Schüz J, Silkaitis K, Solary E, Thomas D, Turkson P, Weiderpass E, Yang H. Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23-24, 2023. Mol Oncol 2024; 18:245-279. [PMID: 38135904 PMCID: PMC10850793 DOI: 10.1002/1878-0261.13575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Accepted: 12/21/2023] [Indexed: 12/24/2023] Open
Abstract
Analyses of inequalities related to prevention and cancer therapeutics/care show disparities between countries with different economic standing, and within countries with high Gross Domestic Product. The development of basic technological and biological research provides clinical and prevention opportunities that make their implementation into healthcare systems more complex, mainly due to the growth of Personalized/Precision Cancer Medicine (PCM). Initiatives like the USA-Cancer Moonshot and the EU-Mission on Cancer and Europe's Beating Cancer Plan are initiated to boost cancer prevention and therapeutics/care innovation and to mitigate present inequalities. The conference organized by the Pontifical Academy of Sciences in collaboration with the European Academy of Cancer Sciences discussed the inequality problem, dependent on the economic status of a country, the increasing demands for infrastructure supportive of innovative research and its implementation in healthcare and prevention programs. Establishing translational research defined as a coherent cancer research continuum is still a challenge. Research has to cover the entire continuum from basic to outcomes research for clinical and prevention modalities. Comprehensive Cancer Centres (CCCs) are of critical importance for integrating research innovations to preclinical and clinical research, as for ensuring state-of-the-art patient care within healthcare systems. International collaborative networks between CCCs are necessary to reach the critical mass of infrastructures and patients for PCM research, and for introducing prevention modalities and new treatments effectively. Outcomes and health economics research are required to assess the cost-effectiveness of new interventions, currently a missing element in the research portfolio. Data sharing and critical mass are essential for innovative research to develop PCM. Despite advances in cancer research, cancer incidence and prevalence is growing. Making cancer research infrastructures accessible for all patients, considering the increasing inequalities, requires science policy actions incentivizing research aimed at prevention and cancer therapeutics/care with an increased focus on patients' needs and cost-effective healthcare.
Collapse
|
3
|
Baumann M, Celis J, Ringborg U, Heitor M, Berns A, Albreht T, Arabadjiev J, Boutros M, Brandenburg M, Canhao H, Carneiro F, Chomienne C, De Lorenzo F, Eggermont AMM, Font A, Garralda E, Goulart M, Henrique R, Lawler M, Maier‐Hein L, Meunier F, Oberst S, Oliveira P, Papatriantafyllou M, Schüz J, Solary E, Valencia A, Vargas R, Weiderpass E, Wilking N. Engaging European society at the forefront of cancer research and care: How discussions at the 5 th Gago Conference on European Science policy led to the Heidelberg Manifesto. Mol Oncol 2023; 17:925-945. [PMID: 36938773 PMCID: PMC10257409 DOI: 10.1002/1878-0261.13423] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2023] [Revised: 03/26/2023] [Accepted: 03/17/2023] [Indexed: 03/21/2023] Open
Abstract
European cancer research stakeholders met in October 2022 in Heidelberg, Germany, at the 5th Gago conference on European Cancer Policy, to discuss the current cancer research and cancer care policy landscape in Europe. Meeting participants highlighted gaps in the existing European programmes focusing on cancer research, including Europe's Beating Cancer Plan (EBCP), the Mission on Cancer (MoC), Understanding Cancer (UNCAN.eu), and the joint action CRANE, and put forward the next priorities, in the form of the Heidelberg Manifesto for cancer research. This meeting report presents all discussions that shed light on how infrastructures can be effectively shaped for translational, prevention, clinical and outcomes cancer research, with a focus on implementation and sustainability and while engaging patients and the public. In addition, we summarize recommendations on how to introduce frameworks for the digitalization of European cancer research. Finally, we discuss what structures, commitment, and resources are needed to establish a collaborative cancer research environment in Europe to achieve the scale required for innovation.
Collapse
Affiliation(s)
- Michael Baumann
- German Cancer Research Center (DKFZ)HeidelbergGermany
- European Academy of Cancer SciencesStockholmSweden
| | - Julio Celis
- European Academy of Cancer SciencesStockholmSweden
- Danish Cancer Society Research CenterCopenhagenDenmark
| | - Ulrik Ringborg
- European Academy of Cancer SciencesStockholmSweden
- Cancer Center KarolinskaKarolinska University HospitalStockholmSweden
| | - Manuel Heitor
- European Academy of Cancer SciencesStockholmSweden
- Center for Innovation, Technology and Policy Research, IN+ @ IS TécnicoUniversity of LisbonPortugal
| | - Anton Berns
- European Academy of Cancer SciencesStockholmSweden
- The Netherlands Cancer InstituteAmsterdamThe Netherlands
| | - Tit Albreht
- National Institute of Public Health of SloveniaLjubljanaSlovenia
- Faculty of MedicineUniversity of LjubljanaSlovenia
| | - Jeliazko Arabadjiev
- Clinic of Medical OncologyUniversity Hospital Acibadem City Clinic TokudaSofiaBulgaria
- Bulgarian Scientific Society of Immuno‐oncology, and MoC BoardSofiaBulgaria
| | - Michael Boutros
- European Academy of Cancer SciencesStockholmSweden
- Division Signaling and Functional GenomicsGerman Cancer Research Center (DKFZ) and Heidelberg UniversityGermany
- DKFZ‐Hector Cancer Institute at the University Medical Center MannheimGermany
| | | | - Helena Canhao
- Comprehensive Health Research Center (CHRC), NOVA Medical SchoolUniversidade Nova de LisboaPortugal
| | - Fatima Carneiro
- European Academy of Cancer SciencesStockholmSweden
- Instituto de Patologia e Imunologia Molecular da Universidade do Porto (Ipatimup)Portugal
- Instituto de Investigação e Inovação em Saúde (i3S), Faculdade de Medicina da Universidade do Porto (FMUP)Portugal
- Centro Hospitalar Universitário de São João (CHUSJ)PortoPortugal
| | | | - Francesco De Lorenzo
- European Academy of Cancer SciencesStockholmSweden
- European Cancer Patient CoalitionBrusselsBelgium
| | - Alexander M. M. Eggermont
- European Academy of Cancer SciencesStockholmSweden
- Department Cancer MedicineCSO Princess Máxima Centre Pediatric Oncology, University Medical Center UtrechtThe Netherlands
- Board of the Comprehensive Cancer Center MunichTechnical University MunichGermany
- Ludwig Maximiliaan UniversityMunichGermany
| | | | - Elena Garralda
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO)BarcelonaSpain
- Cancer Core EuropeAmsterdamThe Netherlands
| | | | - Rui Henrique
- Department of Pathology & Cancer Biology & Epigenetics Group – Research Center of IPO Porto (CI‐IPOP)/RISE@CI‐IPOP (Health Research Network)Portuguese Oncology Institute of Porto (IPO‐Porto)/Porto Comprehensive Cancer Centre Raquel Seruca (P.CCC Raquel Seruca)Portugal
- Department of Pathology and Molecular Immunology, School of Medicine & Biomedical SciencesUniversity of Porto (ICBAS‐UP)Portugal
| | - Mark Lawler
- European Academy of Cancer SciencesStockholmSweden
- FRCPath Patrick G Johnston Centre for Cancer Research, Faculty of Medicine, Health and Life SciencesQueen's University BelfastUK
| | - Lena Maier‐Hein
- Intelligent Medical Systems (IMSY)German Cancer Research Center (DKFZ)HeidelbergGermany
| | - Francoise Meunier
- European Academy of Cancer SciencesStockholmSweden
- Belgian Royal Academy of MedicineBrusselsBelgium
| | - Simon Oberst
- Quality and AccreditationOrganisation of European Cancer InstitutesBrusselsBelgium
| | - Pedro Oliveira
- Nova School of Business and EconomicsCopenhagen Business School & Patient InnovationFrederiksbergDenmark
| | | | - Joachim Schüz
- European Academy of Cancer SciencesStockholmSweden
- International Agency for Research on Cancer (IARC/WHO)LyonFrance
| | - Eric Solary
- European Academy of Cancer SciencesStockholmSweden
- INSERM, U1287 and Department of HematologyGustave Roussy Cancer CenterVillejuifFrance
- Faculté de MédecineUniversité Paris‐SaclayLe Kremlin‐BicêtreFrance
| | - Alfonso Valencia
- Barcelona Supercomputing Center (BSC)BarcelonaSpain
- ICREABarcelonaSpain
| | | | - Elisabete Weiderpass
- European Academy of Cancer SciencesStockholmSweden
- International Agency for Research on Cancer (IARC/WHO)LyonFrance
| | | |
Collapse
|
4
|
Einsele H, Steutel H, Eichhorst B, Göbeler ME, Hochhaus A, Nickel L, von Messling V, Deggerich A, Nettekoven G. [Klinische Studien in der Hämatologie und Onkologie]. Oncol Res Treat 2022; 45 Suppl 1:6-32. [PMID: 35871514 DOI: 10.1159/000525371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Accepted: 06/03/2022] [Indexed: 11/19/2022]
Affiliation(s)
- Hermann Einsele
- Medizinische Klinik und Poliklinik II, Zentrum Innere Medizin (ZIM), Universitätsklinikum Würzburg, Würzburg, Deutschland
| | - Han Steutel
- Verband Forschender Arzneimittelhersteller e.V., Berlin, Deutschland
| | | | - Maria-Elisabeth Göbeler
- Interdisziplinäres Studienzentrum mit ECTU, Universitätsklinikum Würzburg, Würzburg, Deutschland
| | - Andreas Hochhaus
- Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Deutschland
| | - Lars Nickel
- Bundesministerium für Gesundheit, Unterabteilung Arzneimittel, Bonn, Deutschland
| | - Veronika von Messling
- Bundesministerium für Bildung und Forschung, Abteilung 6 «Lebenswissenschaften», Berlin, Deutschland
| | - Anke Deggerich
- Deutsche Forschungsgemeinschaft, Lebenswissenschaften 3: Medizin, Bonn, Deutschland
| | | |
Collapse
|
5
|
Sayan M, Eren MF, Kilic SS, Kotek A, Kaplan SO, Duran O, Cukurcayır F, Babalıoglu I, Or OD, Ozturk GA, Eroglu C, Teke F, Kurtul N, Kutuk T, Bicakci BC, Senyurek S, Aktan M, Mamidanna S, Ohri N, Haffty B, Atalar B. Utilization of radiation therapy and predictors of noncompliance among Syrian refugees in Turkey. BMC Cancer 2022; 22:532. [PMID: 35550042 PMCID: PMC9097407 DOI: 10.1186/s12885-022-09558-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Accepted: 04/17/2022] [Indexed: 11/26/2022] Open
Abstract
Background Access to cancer care is a problem that continues to plague refugees displaced from their home countries. The turbulent political crisis in Syria, which has led to millions of refugees seeking asylum in Turkey, merits further attention. We aimed to study the rate of utilization of radiation therapy among Syrian refugees with cancer living in Turkey in an attempt to identify the contributing factors predictive of non-compliance with prescribed RT. Methods In this retrospective review of 14 institutional databases, Syrian refugee patients in Turkey with a cancer diagnosis from January 2015 to December 2019 who were treated with RT were identified. The demographic data, treatment compliance rates, and toxicity outcomes in these patients were surveyed. Variable predictors of noncompliance such as age, sex, diagnosis, treatment length, and toxicity were studied. The association between these variables and patient noncompliance was determined. Results We identified 10,537 patients who were diagnosed with cancer during the study period, of whom 1010 (9.6%) patients were treated with RT. Breast cancer (30%) and lung cancer (14%) were the most common diagnoses with up to 68% of patients diagnosed at an advanced stage (Stage III, IV). 20% of the patients were deemed noncompliant. Treatment with concurrent chemoradiotherapy (OR 1.61, 95% CI 1.06–2.46, p = 0.023) and living in a refugee camp (OR 3.62, 95% CI 2.43–5.19, p < 0.001) were associated with noncompliance. Age, sex and treatment length were not significantly associated with noncompliance. Conclusions Noncompliance with radiotherapy among Syrian refugees in Turkey remains an area of concern with a multitude of factors contributing to these alarming numbers. Further studies to better ascertain the finer nuances of this intricately complex problem and a global combination of efforts can pave the way to providing a solution.
Collapse
Affiliation(s)
- Mutlay Sayan
- Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street. ASB1 - L2, Boston, MA, 02115, USA.
| | - Mehmet Fuat Eren
- Marmara University Pendik Education and Research Hospital, Istanbul, Turkey
| | | | - Ayse Kotek
- Gaziantep Dr. Ersin Arslan Education and Research Hospital, Gaziantep, Turkey
| | | | - Ozge Duran
- Sanliurfa Mehmet Akif Inan Education and Research Hospital, Sanliurfa, Turkey
| | | | | | | | | | | | | | | | - Tugce Kutuk
- Malatya Education and Research Hospital, Malatya, Turkey
| | | | - Sukran Senyurek
- Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkey
| | | | - Swati Mamidanna
- Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
| | - Nisha Ohri
- Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
| | - Bruce Haffty
- Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
| | | |
Collapse
|
6
|
Ryan KM. In the spotlight: Julio Celis, the Founding Editor of Molecular Oncology. Mol Oncol 2022; 16:3-7. [PMID: 34989122 PMCID: PMC8732337 DOI: 10.1002/1878-0261.13155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Affiliation(s)
- Kevin M. Ryan
- Molecular OncologyFEBS PressCambridgeUK
- Cancer Research UK Beatson InstituteGlasgowUK
| |
Collapse
|
7
|
Ringborg U, Berns A, Celis JE, Heitor M, Tabernero J, Schüz J, Baumann M, Henrique R, Aapro M, Basu P, Beets‐Tan R, Besse B, Cardoso F, Carneiro F, van den Eede G, Eggermont A, Fröhling S, Galbraith S, Garralda E, Hanahan D, Hofmarcher T, Jönsson B, Kallioniemi O, Kásler M, Kondorosi E, Korbel J, Lacombe D, Carlos Machado J, Martin‐Moreno JM, Meunier F, Nagy P, Nuciforo P, Oberst S, Oliveiera J, Papatriantafyllou M, Ricciardi W, Roediger A, Ryll B, Schilsky R, Scocca G, Seruca R, Soares M, Steindorf K, Valentini V, Voest E, Weiderpass E, Wilking N, Wren A, Zitvogel L. The Porto European Cancer Research Summit 2021. Mol Oncol 2021; 15:2507-2543. [PMID: 34515408 PMCID: PMC8486569 DOI: 10.1002/1878-0261.13078] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2021] [Accepted: 08/12/2021] [Indexed: 01/22/2023] Open
Abstract
Key stakeholders from the cancer research continuum met in May 2021 at the European Cancer Research Summit in Porto to discuss priorities and specific action points required for the successful implementation of the European Cancer Mission and Europe's Beating Cancer Plan (EBCP). Speakers presented a unified view about the need to establish high-quality, networked infrastructures to decrease cancer incidence, increase the cure rate, improve patient's survival and quality of life, and deal with research and care inequalities across the European Union (EU). These infrastructures, featuring Comprehensive Cancer Centres (CCCs) as key components, will integrate care, prevention and research across the entire cancer continuum to support the development of personalized/precision cancer medicine in Europe. The three pillars of the recommended European infrastructures - namely translational research, clinical/prevention trials and outcomes research - were pondered at length. Speakers addressing the future needs of translational research focused on the prospects of multiomics assisted preclinical research, progress in Molecular and Digital Pathology, immunotherapy, liquid biopsy and science data. The clinical/prevention trial session presented the requirements for next-generation, multicentric trials entailing unified strategies for patient stratification, imaging, and biospecimen acquisition and storage. The third session highlighted the need for establishing outcomes research infrastructures to cover primary prevention, early detection, clinical effectiveness of innovations, health-related quality-of-life assessment, survivorship research and health economics. An important outcome of the Summit was the presentation of the Porto Declaration, which called for a collective and committed action throughout Europe to develop the cancer research infrastructures indispensable for fostering innovation and decreasing inequalities within and between member states. Moreover, the Summit guidelines will assist decision making in the context of a unique EU-wide cancer initiative that, if expertly implemented, will decrease the cancer death toll and improve the quality of life of those confronted with cancer, and this is carried out at an affordable cost.
Collapse
|
8
|
Baumann M, Bacchus C. Radiation Oncology - Towards a mission-oriented approach to cancer. Mol Oncol 2021; 14:1429-1430. [PMID: 32615032 PMCID: PMC7332219 DOI: 10.1002/1878-0261.12730] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Affiliation(s)
| | - Carol Bacchus
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
9
|
Berns A, Ringborg U, Celis JE, Heitor M, Aaronson NK, Abou‐Zeid N, Adami H, Apostolidis K, Baumann M, Bardelli A, Bernards R, Brandberg Y, Caldas C, Calvo F, Dive C, Eggert A, Eggermont A, Espina C, Falkenburg F, Foucaud J, Hanahan D, Helbig U, Jönsson B, Kalager M, Karjalainen S, Kásler M, Kearns P, Kärre K, Lacombe D, de Lorenzo F, Meunier F, Nettekoven G, Oberst S, Nagy P, Philip T, Price R, Schüz J, Solary E, Strang P, Tabernero J, Voest E. Towards a cancer mission in Horizon Europe: recommendations. Mol Oncol 2020; 14:1589-1615. [PMID: 32749074 PMCID: PMC7400777 DOI: 10.1002/1878-0261.12763] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Accepted: 07/01/2020] [Indexed: 12/26/2022] Open
Abstract
A comprehensive translational cancer research approach focused on personalized and precision medicine, and covering the entire cancer research-care-prevention continuum has the potential to achieve in 2030 a 10-year cancer-specific survival for 75% of patients diagnosed in European Union (EU) member states with a well-developed healthcare system. Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, along with the establishment of interconnected high-quality infrastructures for translational research, clinical and prevention trials and outcomes research, will ensure that science-driven and social innovations benefit patients and individuals at risk across the EU. European infrastructures involving comprehensive cancer centres (CCCs) and CCC-like entities will provide researchers with access to the required critical mass of patients, biological materials and technological resources and can bridge research with healthcare systems. Here, we prioritize research areas to ensure a balanced research portfolio and provide recommendations for achieving key targets. Meeting these targets will require harmonization of EU and national priorities and policies, improved research coordination at the national, regional and EU level and increasingly efficient and flexible funding mechanisms. Long-term support by the EU and commitment of Member States to specialized schemes are also needed for the establishment and sustainability of trans-border infrastructures and networks. In addition to effectively engaging policymakers, all relevant stakeholders within the entire continuum should consensually inform policy through evidence-based advice.
Collapse
|
10
|
Lievens Y, Borras JM, Grau C. Provision and use of radiotherapy in Europe. Mol Oncol 2020; 14:1461-1469. [PMID: 32293084 PMCID: PMC7332207 DOI: 10.1002/1878-0261.12690] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2019] [Revised: 01/07/2020] [Accepted: 04/09/2020] [Indexed: 12/30/2022] Open
Abstract
Radiation therapy is one of the core components of multidisciplinary cancer care. Although ~ 50% of all European cancer patients have an indication for radiotherapy at least once in the course of their disease, more than one out of four cancer patients in Europe do not receive the radiotherapy they need. There are multiple reasons for this underutilisation, with limited availability of the necessary resources – in terms of both trained personnel and equipment – being a major underlying cause of suboptimal access to radiotherapy. Moreover, large variations across European countries are observed, not only in available radiotherapy equipment and personnel per inhabitant or per cancer patient requiring radiotherapy, but also in workload. This variation is in part determined by the country's gross national income. Radiation therapy and technology are advancing quickly; hence, recommendations supporting resource planning and investment should reflect this dynamic environment and account for evolving treatment complexity and fractionation schedules. The forecasted increase in cancer incidence, the rapid introduction of innovative cancer treatments and the more active involvement of patients in the healthcare discussion are all factors that should be taken under consideration. In this continuously changing oncology landscape, reliable data on the actual provision and use of radiotherapy, the optimal evidence‐based demand and the future needs are crucial to inform cancer care planning and address and overcome the current inequalities in access to radiotherapy in Europe.
Collapse
Affiliation(s)
- Yolande Lievens
- Department of Radiation OncologyGhent University Hospital and Ghent UniversityBelgium
| | - Josep M. Borras
- Department of Clinical SciencesIDIBELLUniversity of BarcelonaSpain
| | - Cai Grau
- Department of Oncology and Danish Center for Particle TherapyAarhus University HospitalDenmark
| |
Collapse
|
11
|
Walters C, Harter ZJ, Wayant C, Vo N, Warren M, Chronister J, Tritz D, Vassar M. Do oncology researchers adhere to reproducible and transparent principles? A cross-sectional survey of published oncology literature. BMJ Open 2019; 9:e033962. [PMID: 31892667 PMCID: PMC6955516 DOI: 10.1136/bmjopen-2019-033962] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2019] [Revised: 11/20/2019] [Accepted: 11/22/2019] [Indexed: 02/02/2023] Open
Abstract
OBJECTIVES As much as 50%-90% of research is estimated to be irreproducible, costing upwards of $28 billion in USA alone. Reproducible research practices are essential to improving the reproducibility and transparency of biomedical research, such as including preregistering studies, publishing a protocol, making research data and metadata publicly available, and publishing in open access journals. Here we report an investigation of key reproducible or transparent research practices in the published oncology literature. DESIGN We performed a cross-sectional analysis of a random sample of 300 oncology publications published from 2014 to 2018. We extracted key reproducibility and transparency characteristics in a duplicative fashion by blinded investigators using a pilot tested Google Form. PRIMARY OUTCOME MEASURES The primary outcome of this investigation is the frequency of key reproducible or transparent research practices followed in published biomedical and clinical oncology literature. RESULTS Of the 300 publications randomly sampled, 296 were analysed for reproducibility characteristics. Of these 296 publications, 194 contained empirical data that could be analysed for reproducible and transparent research practices. Raw data were available for nine studies (4.6%). Five publications (2.6%) provided a protocol. Despite our sample including 15 clinical trials and 7 systematic reviews/meta-analyses, only 7 included a preregistration statement. Less than 25% (65/194) of publications provided an author conflict of interest statement. CONCLUSION We found that key reproducibility and transparency characteristics were absent from a random sample of published oncology publications. We recommend required preregistration for all eligible trials and systematic reviews, published protocols for all manuscripts, and deposition of raw data and metadata in public repositories.
Collapse
Affiliation(s)
- Corbin Walters
- Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
| | - Zachery J Harter
- Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
| | - Cole Wayant
- Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
| | - Nam Vo
- Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
| | - Michael Warren
- Internal Medicine, Oklahoma State University Medical Center, Tulsa, Oklahoma, USA
| | - Justin Chronister
- Internal Medicine, Oklahoma State University Medical Center, Tulsa, Oklahoma, USA
| | - Daniel Tritz
- Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
| | - Matt Vassar
- Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
| |
Collapse
|
12
|
Berns A, Ringborg U, Eggermont A, Baumann M, Calvo F, Eggert A, Espina C, Hanahan D, Lacombe D, de Lorenzo F, Oberst S, Philip T, Schüz J, Tabernero J, Celis JE. Towards a Cancer Mission in Horizon Europe. Mol Oncol 2019; 13:2301-2304. [PMID: 31670486 PMCID: PMC6822240 DOI: 10.1002/1878-0261.12585] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
Affiliation(s)
- Anton Berns
- The Netherlands Cancer Institute, Amsterdam, The Netherlands
- European Academy of Cancer Sciences
| | - Ulrik Ringborg
- European Academy of Cancer Sciences
- Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden
| | | | - Michael Baumann
- German Cancer Research Center (DKFZ), Heidelberg, Germany
- German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Fabien Calvo
- Gustave Roussy Cancer Campus Grand Paris, Villejuif, France
| | | | - Carolina Espina
- International Agency for Research on Cancer (IARC/WHO), Lyon, France
| | - Douglas Hanahan
- Swiss Institute for Experimental Cancer Research (ISREC), Federal Institute of Technology in Lausanne (EPFL), and Swiss Cancer Center Leman (SCCL), Lausanne, Switzerland
| | | | | | - Simon Oberst
- Cancer Research UK Cambridge Centre, UK
- Organisation of European Cancer Institutes (OECI)
| | - Thierry Philip
- Organisation of European Cancer Institutes (OECI)
- Institut Curie, Paris, France
| | - Joachim Schüz
- International Agency for Research on Cancer (IARC/WHO), Lyon, France
| | - Josep Tabernero
- Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Spain
| | - Julio E Celis
- European Academy of Cancer Sciences
- Danish Cancer Society Research Centre, Copenhagen, Denmark
| |
Collapse
|
13
|
Ringborg U, Celis JE, Baumann M, Eggermont A, Wild CP, Berns A. Boosting the social impact of innovative cancer research - towards a mission-oriented approach to cancer. Mol Oncol 2019; 13:497-501. [PMID: 30811864 PMCID: PMC6396369 DOI: 10.1002/1878-0261.12464] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Affiliation(s)
- Ulrik Ringborg
- Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden
| | - Julio E Celis
- European Academy of Cancer Sciences, Danish Cancer Society Research Centre, Copenhagen, Denmark
| | - Michael Baumann
- German Cancer Research Center (DKFZ), Heidelberg, Germany
- German Cancer Consortium (DKTK), Heidelberg, Germany
| | | | | | - Anton Berns
- Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| |
Collapse
|
14
|
Wild CP, Espina C, Bauld L, Bonanni B, Brenner H, Brown K, Dillner J, Forman D, Kampman E, Nilbert M, Steindorf K, Storm H, Vineis P, Baumann M, Schüz J. Cancer Prevention Europe. Mol Oncol 2019; 13:528-534. [PMID: 30667152 PMCID: PMC6396376 DOI: 10.1002/1878-0261.12455] [Citation(s) in RCA: 51] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2018] [Accepted: 01/10/2019] [Indexed: 01/11/2023] Open
Abstract
The case for cancer prevention in Europe is the same as for all other parts of the world. The number of cancers is increasing, driven by demographic change and evolution in the exposure to risk factors, while the cost of treating patients is likewise spiralling. Estimations suggest that around 40% of cancers in Europe could be prevented if current understanding of risk and protective factors was translated into effective primary prevention, with further reductions in cancer incidence and mortality by screening, other approaches to early detection, and potentially medical prevention. However, the infrastructure for cancer prevention tends to be fragmented between and within different countries in Europe. This lack of a coordinated approach recently led to the foundation of Cancer Prevention Europe (Forman et al., 2018), a collaborative network with the main aims of strengthening cancer prevention in Europe by increasing awareness of the needs, the associated required resources and reducing inequalities in access to cancer prevention across Europe. This article showcases the need for strengthening cancer prevention and introduces the objectives of Cancer Prevention Europe and its foreseen future role in reducing the European cancer burden.
Collapse
Affiliation(s)
| | - Carolina Espina
- International Agency for Research on Cancer (IARC/WHO)LyonFrance
| | - Linda Bauld
- Usher InstituteCollege of Medicine and Veterinary MedicineUniversity of EdinburghUK
- Cancer Research UKLondonUK
| | | | | | - Karen Brown
- UK Therapeutic Cancer Prevention NetworkLeicester Cancer Research CentreUniversity of LeicesterUK
| | - Joakim Dillner
- Karolinska University LaboratoryKarolinska University HospitalStockholmSweden
| | - David Forman
- International Agency for Research on Cancer (IARC/WHO)LyonFrance
| | - Ellen Kampman
- Division of Human Nutrition and HealthWageningen UniversityThe Netherlands
| | | | | | | | - Paolo Vineis
- Department of Epidemiology and BiostatisticsSchool of Public HealthImperial CollegeLondonUK
| | | | - Joachim Schüz
- International Agency for Research on Cancer (IARC/WHO)LyonFrance
| |
Collapse
|
15
|
Ringborg U. Translational cancer research - a coherent cancer research continuum. Mol Oncol 2019; 13:517-520. [PMID: 30657250 PMCID: PMC6396568 DOI: 10.1002/1878-0261.12450] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2019] [Accepted: 01/14/2019] [Indexed: 11/09/2022] Open
Abstract
The main components of the cancer research continuum are basic/preclinical research, early and late clinical research and, after the adoption of an innovation by the healthcare or health organisations, outcomes research. Translational cancer research, defined as a coherent cancer research continuum, is mandatory to address the increasing burden of cancer effectively. The growing cancer problem can only be significantly modified by concerted action involving prevention to decrease incidence, early detection and treatment to increase the cure rate, and personalised/precision cancer medicine to adapt early detection and treatment to the biology of a tumour with the aim of increasing the cure rate, prolonging survival and improving health-related quality of life. By definition, translational cancer research for therapeutics has a focus on patients' needs and for prevention for individuals at-risk. Consequently, to increase the effectiveness of translational research, the different components of the cancer research continuum need to be better connected to the fundamental aim of a mission-oriented approach to cancer (Celis and Pavalkis, ).
Collapse
Affiliation(s)
- Ulrik Ringborg
- Cancer Center KarolinskaKarolinska University Hospital SolnaStockholmSweden
| |
Collapse
|
16
|
Berns A. Quality-assured research environments for translational cancer research. Mol Oncol 2019; 13:543-548. [PMID: 30628170 PMCID: PMC6396364 DOI: 10.1002/1878-0261.12441] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Revised: 12/13/2018] [Accepted: 12/14/2018] [Indexed: 11/06/2022] Open
Abstract
In order to secure high-quality cancer care for increasing numbers of cancer patients in the upcoming decades, the complete continuum of cancer research and cancer care needs a thorough overhaul, with more emphasis on prevention and early detection, and a greater focus on the development of innovative treatments that are also scrutinised for effectiveness and quality-of-life aspects. Therefore, under-resourced research areas, such as primary prevention, early diagnosis/secondary prevention (Song et al., ; Wild et al., ) and outcomes research (Cavers et al., ), should be given more emphasis, whereas basic, preclinical and clinical cancer research requires more innovation and effective collaboration to develop more effective treatments at an affordable cost. Innovative collaborative research in this translational trajectory requires the participation of well-resourced and well-organised institutions that are committed to high scientific and ethical standards. Offering focused funding to distinct segments of this research continuum concomitant with incentives to aspire to high-quality standards is the most effective route to achieve these goals. Therefore, a rigorous quality assessment system for institutions operating in this research continuum is a high priority.
Collapse
Affiliation(s)
- Anton Berns
- Oncode InstituteThe Netherlands Cancer InstituteAmsterdamThe Netherlands
| |
Collapse
|
17
|
Ernberg I. Education aimed at increasing international collaboration and decreasing inequalities. Mol Oncol 2019; 13:648-652. [PMID: 30677237 PMCID: PMC6396351 DOI: 10.1002/1878-0261.12460] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2019] [Accepted: 01/22/2019] [Indexed: 11/10/2022] Open
Abstract
Educational initiatives in cancer research have to align with the needs of patients, individuals at risk, healthcare systems and public health organisations. The above interests demand strong translational interactions between basic research, clinical/prevention research and entrepreneurship. The resulting synergy between these three entities is expected to stimulate identification of unresolved issues in cancer biology, as well as unmet needs in diagnostics, treatment and prevention. It will also encourage the development of international research collaborations and, in turn, improve access to innovative research infrastructures. Education and dissemination of knowledge and technologies must be a cornerstone of any future European mission-oriented approach to cancer, as it will ensure that new cancer treatments reach all patients within the European Union, and also help reduce gross inequalities in cancer incidence and mortality. A large number of educational institutions ranging from local universities to pan-European organisations have developed excellent educational activities. However, a cancer mission will highlight additional roles for higher education that will complement and provide novel approaches. Educational and training activities should target the general public (dissemination) for primary cancer prevention, as well as the next generation of cancer researchers in basic and clinical research all over Europe. The experiences of patients are also needed to improve health-related quality-of-life and outcomes research. A mission approach to cancer would enhance the exchange of researchers within Europe and worldwide, and prioritise collaborations between Western/Central and Eastern Europe countries. The Comprehensive Cancer Centres (CCCs) will be crucial to train scientific staff in established centres as well as in candidate centres aspiring to join networks of CCCs. In addition, CCCs will have an important role to play by offering educational programmes for the next generation of clinical/research leaders.
Collapse
Affiliation(s)
- Ingemar Ernberg
- Department of Microbiology, Tumor Biology and Cell BiologyKarolinska InstitutetStockholmSweden
| |
Collapse
|
18
|
Lacombe D, Bogaerts J, Tombal B, Maignen F, Osipienko L, Sullivan R, Golfinopoulos V. Late translational research: putting forward a new model for developing new anti-cancer treatments that addresses the needs of patients and society. Mol Oncol 2019; 13:558-566. [PMID: 30561901 PMCID: PMC6396352 DOI: 10.1002/1878-0261.12431] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Accepted: 12/04/2018] [Indexed: 11/08/2022] Open
Abstract
Bringing therapeutic innovation and the latest science to routine patient care, while safeguarding principles of affordability and equality, is a challenging mission in the current complex multi-stakeholder environment. Precision oncology and new approaches to clinical trials (methods and clinical setting) have dramatically changed clinical research and the clinical development of new treatments. Improved understanding of molecular biology and immunology paves the way for innovative pharmacological approaches. However, we argue that the evidence generated during the clinical development of these new products for the purpose of obtaining marketing authorisations often does not address fundamental questions concerning the impact of these new interventions on the most relevant clinical outcomes: namely, quality of life and patient survival. Similarly, patient populations (for example defined by biomarkers), treatment duration, and sequence and combination of treatments within current treatment pathways are often poorly defined by clinical developments for regulatory purposes. Finally, the lack of integrated translational research within the pathway of development is a major limiting factor to delivering cost-effective and affordable, evidence-based care to clinical practice. This leaves many gaps in the knowledge on the efficacy and therapeutic use of medicines, which can impose a significant financial burden on healthcare systems, possibly to the detriment of more cost-effective interventions. We argue that policy changes are required to integrate clinical research and healthcare to inform clinical practice. New routes toward optimising the integration of drug development and care are being proposed to achieve this ultimate goal.
Collapse
Affiliation(s)
| | | | - Bertrand Tombal
- Cliniques Universitaires Saint‐Luc Université Catholique de Louvain BrusselsBelgium
| | - François Maignen
- NICE Scientific AdviceNational Institute for Health and Care ExcellenceLondonUK
| | - Leeza Osipienko
- NICE Scientific AdviceNational Institute for Health and Care ExcellenceLondonUK
| | - Richard Sullivan
- Institute of Cancer Policy, Conflict and Health Research GroupKing's College London & Kings Health Partners Comprehensive Cancer CentreLondon, UK
| | | |
Collapse
|
19
|
Celis JE, Heitor M. Towards a mission-oriented approach to cancer in Europe: an unmet need in cancer research policy. Mol Oncol 2019; 13:502-510. [PMID: 30657635 PMCID: PMC6396358 DOI: 10.1002/1878-0261.12452] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Accepted: 01/15/2019] [Indexed: 11/13/2022] Open
Abstract
Today, cancer is a significant challenge for society, healthcare systems and the growing number of affected patients and their families. This article argues that new paradigms and conditions for responsible science and innovation policy across the European Union (EU) require (i) the collective action of Research & Development institutions, (ii) a system approach to health systems, higher education and patient organizations, and (iii) new initiatives to encourage international cooperation across an enlarged Europe; no single country can successfully fight the disease(s) on its own. Recently, a cancer mission was proposed (Celis and Pavalski, ), the origins of which are rooted in the continuous efforts of the research community, cancer patient organizations, member states and the European Commission during nearly two decades to address the fragmentation and lack of coordination of European cancer research; these efforts led to the creation of Cancer Core Europe and Cancer Prevention Europe, consortia aimed at linking therapeutic and prevention geometries. Ultimately, the platform/infrastructure will be composed of networks of Comprehensive Cancer Centres and cancer research centres across Europe to reach the critical mass of expertise, patients and collaborative portfolio of projects that are necessary to promote science-driven and social innovations in the era of personalized (precision) cancer medicine. Employing a mission-oriented approach to achieve the goal of ensuring a long life expectancy for three out of four cancer patients by 2030 is likely to have a particularly positive impact on the way European citizens' value science and knowledge. It will change the lives of many families across Europe and beyond and should be oriented to ensure that Europe is at the forefront when it comes to quality of life. It is our collective responsibility to ensure that not a single person or region in Europe is left behind.
Collapse
Affiliation(s)
- Julio E. Celis
- European Academy of Cancer SciencesDanish Cancer Society Research CentreCopenhagenDenmark
| | - Manuel Heitor
- Minister for Science, Technology and Higher EducationPortugal
| |
Collapse
|
20
|
A report from a conference jointly organised by the European Academy of Cancer Sciences and the Pontifical Academy of Sciences, The Vatican, November 16-17, 2018. Mol Oncol 2019; 13:511-516. [PMID: 30811840 PMCID: PMC6396569 DOI: 10.1002/1878-0261.12436] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Cancer is a massive challenge with a significant impact on society, healthcare systems, the economy and an increasing number of patients and their families. To help meet this societal challenge, the European Commission has recently proposed a mission‐oriented approach to cancer in Horizon Europe, and about 60 participants met at the Vatican to discuss a mission‐oriented approach to cancer in Europe, as documented in this report. Painting: Rowe, Ernest Arthur. Courtyard of the Casina Pio IV (ca. 1911–1913).![]()
Collapse
|
21
|
de Lorenzo F, Apostolidis K. The European Cancer Patient Coalition and its central role in connecting stakeholders to advance patient-centric solutions in the mission on cancer. Mol Oncol 2019; 13:653-666. [PMID: 30657631 PMCID: PMC6396363 DOI: 10.1002/1878-0261.12448] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Accepted: 01/06/2019] [Indexed: 11/08/2022] Open
Abstract
There is an urgent need for solutions to the economic and social inequalities in cancer care that still exist in many European countries. Patient preferences, ‘big data’, mobile digital technology and molecular and genomic profiling are among the innovative research topics that connect cancer patients to comprehensive cancer centres, and link translational research to cancer diagnosis, treatment and care. The question is whether Europe can deliver the complex infrastructure needed for universal coverage and equitable access to cancer care. The European Cancer Patient Coalition (ECPC), the leading ‘umbrella’ cancer patient organisation in Europe, has a central role in bringing the unmet needs of patients with cancer to the forefront of cancer policy, care and research. The ECPC is a respected and reliable partner in the oncology community and has effectively collaborated with institutional stakeholders and organisations, as well as with the European Commission, on cancer research projects and in the development of tools to advance health care and cancer policies at the European and national level. The ECPC believes that innovation cannot emerge and grow without patient involvement and is fully committed to increasing patient education and contribution in cancer research through its active participation in various European cancer research programmes and educational resources. The ECPC is expected to play a major role in the mission on cancer, given its previous achievements in policy and research to help overcome the inequalities in cancer prevention, treatment, rehabilitation and survivorship care. The mission on cancer will be facilitated by active collaboration between patient organisations and scientists, clinicians, politicians and industry, with the aim of identifying important research questions regarding quality of life and social issues for cancer patients of all ages.
Collapse
|
22
|
Eggermont AMM, Apolone G, Baumann M, Caldas C, Celis JE, de Lorenzo F, Ernberg I, Ringborg U, Rowell J, Tabernero J, Voest E, Calvo F. Cancer Core Europe: A translational research infrastructure for a European mission on cancer. Mol Oncol 2019; 13:521-527. [PMID: 30657633 PMCID: PMC6396377 DOI: 10.1002/1878-0261.12447] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2018] [Revised: 12/28/2018] [Accepted: 01/11/2019] [Indexed: 12/30/2022] Open
Abstract
Cancer Core Europe is a European legal alliance consisting of seven leading cancer centres – most of them Comprehensive Cancer Centres (CCCs) – with a single portal system to engage in various research projects with partners. Cancer Core Europe was established to create a sustainable, high‐level, shared research infrastructure platform hosting research collaborations and task forces (data sharing, clinical trials, genomics, immunotherapy, imaging, education and training, and legal and ethical issues), with a controlled expansion agenda. Translational cancer research covers the cancer research continuum from basic to preclinical to early clinical, late clinical, and outcomes research. Basic–preclinical research serves as the ‘engine’ for early clinical research by bridging the early translational research gap and is the primary and current focus of the consortium as exemplified by the launching of the Basket of Baskets trial, Europe's largest precision cancer medicine trial. Inspired by the creation of Cancer Core Europe, the prevention community established Cancer Prevention Europe, a consortium of ten cancer prevention centres aimed at supporting the complete prevention research continuum. Presently, Cancer Core Europe and Cancer Prevention Europe are integrating therapeutics and prevention strategies to address in partnership the widening cancer problem. By providing innovative approaches for cancer research, links to healthcare systems, development of quality‐assured multidisciplinary cancer care, and assessment of long‐term outcomes, the virtual infrastructure will serve as a hub to connect and interact with other centres across Europe and beyond. Together, Cancer Core Europe and Cancer Prevention Europe are prepared to function as a central engine to tackle, in collaboration with various partners, a potential ‘mission on cancer’ addressing the cancer burden.
Collapse
Affiliation(s)
| | - Giovanni Apolone
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | | | - Carlos Caldas
- Department of Oncology, Cancer Research UK Cambridge Institute, University of Cambridge, UK
| | - Julio E Celis
- Danish Cancer Society Research Centre, Copenhagen, Denmark
| | - Francesco de Lorenzo
- European Cancer Patient Coalition, Brussels, Belgium.,Italian Federation of Cancer Patients Organisations, Rome, Italy
| | - Ingemar Ernberg
- Cancer Centre Karolinska, Karolinska Institutet, Stockholm, Sweden
| | - Ulrik Ringborg
- Cancer Centre Karolinska, Karolinska Institutet, Stockholm, Sweden
| | - John Rowell
- Gustave Roussy Cancer Campus Grand Paris, Villejuif, France Cancer Core Europe, France
| | - Josep Tabernero
- Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain
| | - Emile Voest
- Netherlands Cancer Institute, Amsterdam, The Netherlands
| | | |
Collapse
|
23
|
Brandts CH. Innovating the outreach of comprehensive cancer centers. Mol Oncol 2019; 13:619-623. [PMID: 30657632 PMCID: PMC6396353 DOI: 10.1002/1878-0261.12451] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2019] [Accepted: 01/12/2019] [Indexed: 11/16/2022] Open
Abstract
In many countries, a majority of cancer patients are not treated at comprehensive cancer centers. Even for those that are, parts of the treatment or follow‐up may be carried out in local community hospitals or in private practices. How to assure quality in cancer care and create innovation? How to integrate decentralized versus centralized patient care, education, and cancer research? Outlined here is a 360° view of outreach to include all stakeholders—most importantly patients and their families, patient advocacy groups, healthcare providers, health insurers, and policymakers.
Collapse
Affiliation(s)
- Christian H Brandts
- Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, University Cancer Center Frankfurt (UCT), Germany
| |
Collapse
|
24
|
Oberst S. Bridging research and clinical care - the comprehensive cancer centre. Mol Oncol 2019; 13:614-618. [PMID: 30628155 PMCID: PMC6396367 DOI: 10.1002/1878-0261.12442] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Revised: 12/14/2018] [Accepted: 12/21/2018] [Indexed: 12/29/2022] Open
Abstract
Comprehensive cancer centres (CCCs) are at the heart of the landscape of cancer research, education and care in Europe. They are vital hubs where the historic gaps in the research to clinical care continuum are bridged. CCCs have established hallmarks, but a greater emphasis is needed in Europe to create more effective CCCs using the partnership model of university medical centres and university research departments and institutes. This review will summarise the organisational structures and processes essential for producing quality outcomes for patients and effectiveness in the translational process. The Organisation of European Cancer Institutes and European Academy of Cancer Sciences have established complementary quality accreditations systems to test the clinical and research excellence of CCCs. The EU should have an ambition to create more CCCs based on university hospitals, for each 5-10 million population and in every Member State.
Collapse
|
25
|
Joos S, Nettelbeck DM, Reil-Held A, Engelmann K, Moosmann A, Eggert A, Hiddemann W, Krause M, Peters C, Schuler M, Schulze-Osthoff K, Serve H, Wick W, Puchta J, Baumann M. German Cancer Consortium (DKTK) - A national consortium for translational cancer research. Mol Oncol 2019; 13:535-542. [PMID: 30561127 PMCID: PMC6396349 DOI: 10.1002/1878-0261.12430] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2018] [Accepted: 11/26/2018] [Indexed: 11/16/2022] Open
Abstract
The German Cancer Consortium (‘Deutsches Konsortium für Translationale Krebsforschung’, DKTK) is a long‐term cancer consortium, bringing together the German Cancer Research Center (DKFZ), Germany's largest life science research center, and the leading University Medical Center‐based Comprehensive Cancer Centers (CCCs) at seven sites across Germany. DKTK was founded in 2012 following international peer review and has positioned itself since then as the leading network for translational cancer research in Germany. DKTK is long term funded by the German Ministry of Research and Education and the federal states of each DKTK partner site. DKTK acts at the interface between basic and clinical cancer research, one major focus being to generate suitable multisite cooperation structures and provide the basis for including higher numbers of patients and facilitate effective collaborative forward and reverse translational cancer research. The consortium addresses areas of high scientific and medical relevance and develops critical infrastructures, for example, for omics technologies, clinical and research big data exchange and analysis, imaging, and clinical grade drug manufacturing. Moreover, DKTK provides a very attractive environment for interdisciplinary and interinstitutional training and career development for clinician and medical scientists.
Collapse
Affiliation(s)
- Stefan Joos
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Dirk M Nettelbeck
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Anette Reil-Held
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Katja Engelmann
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Alexandra Moosmann
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Angelika Eggert
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,Charité, Berlin, Germany
| | - Wolfgang Hiddemann
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,Ludwig-Maximilians-Universität München, München, Germany
| | - Mechthild Krause
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,University Cancer Center, Dresden, Germany
| | - Christoph Peters
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,Comprehensive Cancer Center Freiburg (CCCF), Germany
| | - Martin Schuler
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,West German Cancer Center, University Hospital Essen, Germany
| | - Klaus Schulze-Osthoff
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,Medical Faculty, Comprehensive Cancer Center, Tübingen, Germany
| | - Hubert Serve
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,University Cancer Center, University Hospital Frankfurt (UCT), Germany
| | - Wolfgang Wick
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany.,National Center of Tumor Diseases (NCT), Heidelberg, Germany.,Heidelberg University Hospital, Heidelberg, Germany
| | - Josef Puchta
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Michael Baumann
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
26
|
Adami H, Berns A, Celis JE, de Vries E, Eggermont A, Harris A, zur Hausen H, Pelicci PG, Ringborg U. European Academy of Cancer Sciences - position paper. Mol Oncol 2018; 12:1829-1837. [PMID: 30241109 PMCID: PMC6210050 DOI: 10.1002/1878-0261.12379] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Accepted: 09/04/2018] [Indexed: 11/20/2022] Open
Abstract
The European Academy of Cancer Sciences (EACS) is an independent advisory body of well-recognised medical specialists and researchers striving to create a compelling interactive continuum of cancer research, from innovative basic research to implementation of state-of-the-art evidence-based cancer care and prevention. Achieving the above will entail bridging high-quality basic and preclinical cancer research to research on prevention, early detection and therapeutics as well as improving coordination of translational research efforts across Europe. The latter is expected to be expedited through quality assuring translational cancer research in Comprehensive Cancer Centres - entities that link research with the healthcare system - and networks of cancer research centres. Achieving a critical mass of expertise, resources and patients is crucial. Improving late translational research, which involves clinical studies to assess effectiveness, and added value for the health care is also a high priority. Both high-quality Big Data collections and the intelligent use of these data will promote innovation in cancer research and support outcomes research to assess clinical utility, quality of cancer care and long-term follow-up of treated patients. The EACS supports the mission-oriented approach recently proposed by the European Commission in Horizon Europe to deal with major challenges and would like to persuade the EU and its member states to formally launch a mission in cancer to boost and streamline the cancer research continuum in Europe. Building a coherent translational cancer research continuum with a focus on patients and individuals at risk will require, however, foresight as well as the extensive and continuous provision of evidence-based advice to inform policy.
Collapse
Affiliation(s)
| | - Anton Berns
- Netherlands Cancer InstituteAmsterdamThe Netherlands
| | | | - Elisabeth de Vries
- University Medical Center Groningen – University of GroningenThe Netherlands
| | | | | | | | | | | |
Collapse
|
27
|
Calvo F, Apolone G, Baumann M, Caldas C, Celis JE, de Lorenzo F, Ernberg I, Ringborg U, Rowell J, Tabernero J, Voest E, Eggermont A. Cancer Core Europe: A European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century. Eur J Cancer 2018; 103:155-159. [PMID: 30241002 DOI: 10.1016/j.ejca.2018.08.023] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2018] [Accepted: 08/31/2018] [Indexed: 10/28/2022]
Abstract
Translational cancer research covers the whole cancer research continuum from basic to preclinical to early clinical, late clinical and outcomes research. Basic-preclinical research is the "engine" for early clinical research bridging the early translational research gap. Cancer Core Europe has been created to construct a sustainable, high level, shared research infrastructure platform with research collaborations and taskforces (data sharing, clinical trials, genomics, immunotherapy, imaging, legal & ethical problems, and education & training) having representatives from all seven member centres, in a controlled expansion model. In parallel, a consortium of ten cancer prevention centres was established, Cancer Prevention Europe, to support the complete cancer prevention research continuum. Cancer Core Europe is launching at present the Basket of Baskets trial, which is the largest personalized cancer medicine trial effort in Europe. At present, Cancer Core Europe and Cancer Prevention Europe are in the process of integrating therapeutics and prevention strategies to address in partnership the increasing cancer problem. By offering innovative approaches for cancer research, links to the healthcare systems, development of quality-assured multidisciplinary cancer care, as well as the assessment of long-term outcomes, the infrastructure is expected to serve as a hub to connect with other centres in Europe as well as on other continents. In this manner Cancer Core Europe and Cancer Prevention Europe prepare to tackle the "Mission on Cancer", with infrastructure and proofs of concept for therapeutics and prevention, research for assessment of effectiveness, health economics and added value for patients and the healthcare systems.
Collapse
Affiliation(s)
| | | | | | - Carlos Caldas
- Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, UK
| | - Julio E Celis
- Danish Cancer Society Research Centre, Copenhagen, Denmark
| | - Franceso de Lorenzo
- European Cancer Patient Coalition, Brussels, Belgium; Italian Federation of Cancer Patients Organisations, Rome, Italy
| | - Ingemar Ernberg
- Cancer Centre Karolinska, Karolinska Institutet, Stockholm, Sweden
| | - Ulrik Ringborg
- Cancer Centre Karolinska, Karolinska Institutet, Stockholm, Sweden
| | | | - Josep Tabernero
- Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain
| | - Emile Voest
- Netherlands Cancer Institute, Amsterdam, The Netherlands
| | | |
Collapse
|
28
|
Forman D, Bauld L, Bonanni B, Brenner H, Brown K, Dillner J, Kampman E, Manczuk M, Riboli E, Steindorf K, Storm H, Espina C, Wild CP. Time for a European initiative for research to prevent cancer: A manifesto for Cancer Prevention Europe (CPE). J Cancer Policy 2018. [DOI: 10.1016/j.jcpo.2018.07.001] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
29
|
Philip T, Almouzni G, Poortmans P. Vision 2030 for the optimal approach to cancer research and care in Europe: A mission or a network of networks? TUMORI JOURNAL 2018; 105:265-270. [PMID: 29911501 DOI: 10.1177/0300891618783655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
INTRODUCTION A mission-oriented approach to cancer care in Europe was proposed by Julio Celis and Dainius Pavalkis in 2017. The major proposed objective is to achieve long-term survival of 3 out of 4 cancer patients by 2030. BACKGROUND The authors are president or president-elect of Organization of European Cancer Institutes (OECI) EU Life or European Cancer Community Organization (ECCO). RESULTS The goal is laudable and ambitious. However, it can only be successful if it is coordinated with active involvement of all stakeholders and interacts with an already well-organized, recognized, and certified European Accreditation and Designation quality approach to identify and select the potential candidates to participate in such a virtual network. CONCLUSIONS The building of a virtual European Cancer Institute based on coordinated networks should refer to unquestioned criteria using a solid and proven methodology operated by an independent arbitration body. The cancer community must share a fundamental responsibility to act collectively and in today's era of the World Wide Web, it is time to think out of the box and consider the possibility of establishing networks of networks.
Collapse
Affiliation(s)
| | - Geneviève Almouzni
- 2 Institut Curie Research Center, PSL University, CNRS, UMR3664, Sorbonne Universités, UPMC Paris, France
| | - Philip Poortmans
- 3 Marie Curie Professor Paris Science & Lettres, Institut Curie, Paris, France
| |
Collapse
|